

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



GENOR BIOPHARMA HOLDINGS LIMITED

嘉和生物藥業（開曼）控股有限公司

(incorporated in the Cayman Islands with limited liability)

(Stock Code: 6998)

VOLUNTARY ANNOUNCEMENT

NATIONAL MEDICAL PRODUCTS ADMINISTRATION ACCEPTS NEW DRUG APPLICATION FOR GB491 (LEROCICLIB)

The announcement is made by Genor Biopharma Holdings Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis to inform the shareholders and potential investors of the Company about the latest business updates of the Group.

The board of directors of the Company (the “**Board**”) announces that, on 13 March 2024, the China National Medical Products Administration (the “**NMPA**”) officially accepted the new drug application (“**NDA**”) for GB491 (Lerociclib) combined with Letrozole for the treatment of HR-positive, HER2-negative patients with advanced breast cancer who have not previously undergone systemic antitumor therapy.

Previously, the NDA for GB491 (Lerociclib) in combination with Fulvestrant as the treatment of HR+/HER2- locally advanced or metastatic breast cancer patients with disease progression following previous endocrine therapy was accepted by the NMPA on 28 March 2023, and has successfully completed clinical on-site inspection.

About GB491 (Lerociclib)

GB491 (Lerociclib) is a highly selective oral CDK4/6 inhibitor for the treatment of breast cancer. It was developed by the Company and G1 Therapeutics, Inc. (Nasdaq: GTHX) (“**G1 Therapeutics**”). The Company has in-licensed exclusive rights of GB491 (Lerociclib) from G1 Therapeutics in certain APAC countries excluding Japan since June 2020.

Cautionary Statement required by Rule 18A.05 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited: The Company cannot guarantee that it will be able to develop, or ultimately market GB491 (Lerociclib) successfully. Shareholders and potential investors of the Company are advised to exercise due care when dealing in the shares of the Company.

By Order of the Board
Genor Biopharma Holdings Limited
Dr. Guo Feng
Chief Executive Officer and Chairman

Hong Kong, 13 March 2024

As at the date of this announcement, the Board comprises Dr. GUO Feng (Chief Executive Officer and Chairman) as an executive director; Dr. LYU Dong, Mr. YU Tieming and Mr. LIU Yi as non-executive directors; Mr. ZHOU Honghao, Mr. FUNG Edwin and Mr. CHEN Wen as independent non-executive directors.